.Pharmacolibrary.Drugs.ATC.L.L01XL07

Information

name:IdecabtageneVicleucel
ATC code:L01XL07
route:intravenous
compartments:0
dosage:300mg
volume of distribution:1L
clearance:0
other parameters in model implementation

Idecabtagene vicleucel is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy used for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy. It is currently FDA and EMA approved.

Pharmacokinetics

As a CAR T-cell therapy, idecabtagene vicleucel does not have traditional pharmacokinetic parameters (absorption, distribution, metabolism, elimination) associated with small molecule or typical biologic drugs. Instead, expansion and persistence of transduced CAR T-cells are measured in peripheral blood. Published sources do not provide classic PK parameters such as volume of distribution or clearance.

References

    Revisions


    Generated at 2025-08-11T18:21:04Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos